Actual - Finance

Much of the ?1 ? trillion of personal debt in the UK can be attributed to cred

According to USFDA, a combination product is one composed of any combination of a drug and device; biological product and device; drug and biological product

it card debt with many people still spending well beyond their means.

Accordi

; or drug, device, and biological product and fixed dose combination would include two or more combinations of drug.

Examples of combination products may in

ng to figures from Credit Action, the average interest rate on credit card len

lude drug-coated devices, drugs packaged with delivery devices in medical kits, and drugs and devices packaged separately but intended to be used together.

ding is currently 17.02% - a whopping 12% above base rate at the start of 2007

here is enormous increase in the number of combination products entering the market in the recent years. Combination products have proven advantages but fixe

. With rates that high, it becomes even more shocking to know that credit card

d dose combinations are still in the process of convincing regulatory authority on their advantages over the single ingredient formulations.

Combination pro

balances bearing interest was 75.1% as of October last year.

But what’s the b

ucts have become life saving products for the pharmaceutical companies who doesn’t have many innovative molecules in their product pipeline and have been inc

est method for servicing credit card debt? One possible solution is a debt con

easingly used in the product life cycle management. Even the companies having product patents are trying to extend their product life cycle through the combi

solidation loan which might be even more tempting in the wake of increased mor

nation products and maximize the revenues. But the companies involved in this practice are overlooking that they are burdening the patients both economically

tgage repayments after the Bank of England’s decision to raise the base rate o

and physically. They need to rightly judge the benefits of the combination products and they have to even look at the risks involved when combining the produ

nce more.

Rolling up all of your outgoings into one interest friendly lump su

ts. Some of the combination products were well accepted by physicians while others suffered. Companies involved in development of combination products are fi

might be the best decision you make all year. But that’s only if you manage t

ding difficulty in defining their combination products and facing various challenges from selecting a combination to marketing it.

Following aspects would a

o secure the right agreement that makes sound financial sense to you.

However

dd to the challenges in developing combination products:

Which markets to tap where the combination products can do fairly well?
Which combination prod

, a debt consolidation loan can carry hidden costs such as fines from credit c

cts are meaningful and rational?
Which therapeutic categories to select?
Which Combinations can address unmet needs of the patients?
Do combin

ard companies for settling balances and transferring the debt.

If you have de

tions increase the patient compliance?
What would be the developing cost?
How to tackle the risks encountered during combination product developmen

bts of over ?15,000 of credit card debt you might even consider an Individual

t?

As combination products don't fit into the traditional categories of drugs, medical devices, or biological products, the USFDA is in the process of devel

oluntary Arrangement or IVA where by you wipe off a large sum of the money you

ping new procedures for reviewing their safety, efficacy and quality.

Professional from academic institutions, pharmaceutical industries, health care indust

owe, and repay the rest in set monthly installments. However, this is a measu

y and representatives from various regulatory agencies are working out to design the regulatory requirements for manufacture and sale of combination products

re that should only be considered in the most extreme cases.

Whatever your pr

.

As there is an increasing trend of the combination products companies manufacturing such products should be able to tackle the problems involved in the de

eference might be for servicing credit card debt, you can find useful informat

elopment. They need to be wiser in analyzing the market trends and the regulatory requirements.

Companies that provide selfless information through particip

ion and links at the Credit Card Debt Site.

Don't forget to rate this article

tion in industry events and feedback to regulatory authorities would be able to face the challenges and will be successful in developing combination products

HTTP = HTML link (for blogs, profiles,phorums):
<a href="http://www.actual.org.ua/article/99986/actual-Credit-Card-Debt-WILL-Continue-to-Be-a-Problem.html">Credit Card Debt WILL Continue to Be a Problem</a>

BB link (for phorums):
[url=http://www.actual.org.ua/article/99986/actual-Credit-Card-Debt-WILL-Continue-to-Be-a-Problem.html]Credit Card Debt WILL Continue to Be a Problem[/url]

Learn key measures that will lead to system implementation project success. Understand key steps in a project that will keep your project on track and help you deliver not only what was actually requested, but deliver what your customers and sponsors understand they requested!

Recipients typically view the preview pane for just a few seconds - then it's either delete or open. Find out how to make the most of the top two inches of your email in order to generate the best response.

Have you been thinking about consolidating credit card or other debt? Are you worried because you have a less than perfect credit history? There are plenty choices available today to help you consolidate your debt.

Tags

Links

Actual - Credit Card Debt WILL Continue to Be a Problem

Related Articles: